Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Download Data

Theseus Pharmaceuticals Inc Sales to Operating Cash Flow Ratio 2 year CAGR for the year ending December 31, 2023

Theseus Pharmaceuticals Inc Sales to Operating Cash Flow Ratio 2 year CAGR is NA for the year ending December 31, 2023. Sales to operating cash flow ratio measures the revenue generated by a company relative to its operating cash flow. It is calculated by dividing the revenue by the operating cash flow. This ratio provides insights into the efficiency of revenue generation compared to the company's operating cash flow. A higher sales to operating cash flow ratio suggests better revenue generation efficiency. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Theseus Pharmaceuticals Inc Sales to Operating Cash Flow Ratio for the year ending December 31, 2022 was -0.00, a 0.00% change year over year.
Theseus Pharmaceuticals Inc Sales to Operating Cash Flow Ratio for the year ending December 31, 2021 was -0.00, a 0.00% change year over year.
Theseus Pharmaceuticals Inc Sales to Operating Cash Flow Ratio for the year ending December 31, 2020 was -0.00, a 0.00% change year over year.
Theseus Pharmaceuticals Inc Sales to Operating Cash Flow Ratio for the year ending December 31, 2019 was -0.00.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends